Lupin arm to commercialise YUVEZZI eye drop across key European markets

Lupin's VISUfarma BV has secured exclusive rights for YUVEZZI in key European markets. This ophthalmic product treats loss of clear close-up vision in adults. VISUfarma will undertake regulatory activities and commercialization of the eye drop. The agreement includes a strategic investment and potential milestone payments. YUVEZZI represents a significant advancement in eye care for presbyopia.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/bm03Nq4
via IFTTT